newsfilter
← Latest News
GlobeNewswire·

Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

  • Liquidia Corporation executives Dr. Roger Jeffs & Michael Kaseta will present at the 2026 Jefferies Global Healthcare Conference on November 17 at 10 a.m. ET/3 p.m. BT in London.
  • The fireside chat will provide an update on the company's business & is accessible via the Investors page at liquidia.com/investors/events-and-presentations.
  • A replay of the webcast will be archived on the company website for at least 30 days.
  • Liquidia focuses on treating respiratory & vascular diseases using its proprietary PRINT Technology.
  • The company markets YUTREPIA, an inhaled treprostinil powder approved for pulmonary arterial hypertension & in development for Raynaud's phenomenon secondary to systemic sclerosis.
  • Liquidia is developing L606, an investigational twice-daily extended-release treprostinil formulation via a next-generation nebulizer for pulmonary arterial hypertension & pulmonary hypertension associated with interstitial lung disease.
Company
Liquidia Technologies, Inc.
Keywords
Nasdaq:LQDA, Liquidia Technologies, Inc.